Antibiotic developer Melinta files for bankruptcy

  02 January 2020

Drug maker Melinta Therapeutics today filed for Chapter 11 bankruptcy, becoming the second antibiotic developer this year to be forced into bankruptcy because of financial problems.

The company said the filing is part of a restructuring agreement with lenders, and that it plans to continue operating while it works to complete the transaction through the Chapter 11 proces

Further reading: CIDRAP
Author(s): Chris Dall
Smart Innovations  
Back

OUR UNDERWRITERS

Unrestricted financial support by:

Antimicrobial Resistance Fighter Coalition

Evotec

JSS University





Technology Database

Display your AMR Technology, Product and Service

Suppliers and Users of Technologies, Products and Services benefit from CAPI.
CAPI (Continuous AMR Partnering Initiative) unites Suppliers and Users worldwide with the aim to add to the curbing of AMR.

Read more and make your own Technology Page >>
What is going on with AMR?
Stay tuned with remarkable global AMR news and developments!